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Letter to the editor
Response to Covey
Brian Hitsman, Bonnie Spring, Belinda Borrelli, Dennis McChargue,
Raymond Niaura
To the Editor:
Dr. Covey asserts that our meta-analysis of the
association between history of major depression and
smoking treatment outcome (Hitsman, Borrelli,
McChargue, Spring, & Niaura, 2003) was flawed
because we did not limit our analysis to participants
randomized to placebo or alternative least intensive
treatment condition. Hitsman et al. (2003) reported a
lack of association between history of major depres-
sion and treatment outcome, for both short-
(ƒ3 months) and long-term (§6 months) abstinence.
The effect size estimate for short-term abstinence was
statistically nonsignificant and near zero, dz~2.05,
95% confidence interval (CI)~2.14, 2.04, p~.18.
Only two of 13 studies showed a significant association
between history of depression and short-term abstinence.
Similarly, the effect size for long-term abstinence was
statistically nonsignificant and approached zero,
dz~2.05, 95% CI~2.15, 2.04, p~.21), with only
one of 12 studies reporting a significant association.
In support of her claim, Dr. Covey cites a
bupropion study by Smith et al. (2003), unpublished
when we prepared our meta-analysis, which reported
that placebo-treated smokers with a history of major
depression were significantly less likely than history
negative smokers to achieve either short- or long-term
abstinence.
To address Dr. Covey’s concern, we re-analyzed the
original data restricting the sample in each study to
participants randomized to placebo or alternative least
intensive treatment condition.1 Next, we performed
a re-analysis further restricted to placebo or the least
intensive treatment condition of those studies that
specifically tested an antidepressant treatment
(antidepressant medications or mood management
treatment).2 Finally, although our call for manuscripts
under review or in press did not elicit the Smith et al.
(2003) study, we report both sets of meta-analyses
with and without the Smith et al. (2003) study.
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2The sample of studies for the ‘‘antidepressant studies
only’’ re-analysis included the studies involving paroxetine
(Killen et al., 2000), fluoxetine (Keuthen et al., 2000),
bupropion (Hayford et al., 1999), nortriptyline (Hall et al.,
1998), and mood management treatment (Hall et al., 1994;
Hall et al., 1996; Mun˜oz et al., 1997). As in the re-analysis
of the original studies, this analysis was conducted with
and without the bupropion study by Smith et al. (2003).
1The placebo or least intensive treatment condition for the
studies in Hitsman et al. (2003) are as follows: placebo
clonidinezintensive behavioral treatment (Glassman et al.,
1988; Covey et al., 1993; Glassman et al., 1993),
psychoeducationznicotine gum (Hall, Mun˜oz, & Reus,
1994), relapse preventionzaversive smoking (Ginsberg
et al., 1995), health educationznicotine gum (Hall et al.,
1996), psychoeducation mail intervention (Mun˜oz et al.,
1997), placebo nortriptylinezhealth education (Hall
et al., 1998), placebo naltrexonezintensive behavioral
treatment (Covey, Glassman, & Stetner, 1999), placebo
bupropionzbrief behavioral treatment (Hayford et al.,
1999), minimal behavioral treatment (Niaura et al., 1999),
placebo paroxetineznicotine patchzbrief behavioral
treatment (Killen et al., 2000), and placebo fluoxetinez
intensive behavioral treatment (Keuthen et al., 2000). For
the study by Smith et al. (2003), the least intensive
treatment condition was placebo bupropionzplacebo
patchzbrief behavioral treatment.
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As in Hitsman et al. (2003), we extracted data on
point-prevalence abstinence that had been derived on
an intent-to-treat basis for the least intensive treat-
ment arm. Effect size estimates were weighted by
study sample sizes. A negative sign indicated lower
abstinence rates for history positive smokers. Follow-
ing Cohen’s (1987) classification guideline, a small
effect is .20, a medium effect is .50, and a large effect
is .80. The placebo-controlled nortriptyline study by
Prochazka et al. (1998) could not be included in the
re-analysis because no data were reported on history
of depression6treatment condition.
Table 1 shows the association between history of
major depression and cessation outcome for the least
intensive treatment. Re-analysis of the sample of
studies in Hitsman et al. (2003) revealed a small and
nonsignificant association between depression history
and short-term abstinence among participants receiv-
ing placebo or alternative least intensive treatment.
Re-analysis including Smith et al. (2003) did not
change either the magnitude or statistical significance
of the aggregated effect size. Re-analysis of anti-
depressant treatment studies with and without Smith
et al. (2003) also yielded similar results. The tests of
homogeneity for these analyses indicated a consistency
among individual study effect sizes.
Table 2, which displays the effect size estimates for
the parallel long-term outcomes, shows a similar
pattern of results. Re-analysis of the sample of studies
in Hitsman et al. (2003) revealed a homogeneous
effect size that was small and statistically nonsignifi-
cant. These results, which were unchanged by adding
the study by Smith et al. (2003) or by restricting the
meta-analysis to studies involving depression treat-
ment, again indicate that there is no statistically
significant difference in long-term abstinence between
smokers positive versus negative for history of
depression. The aggregate effect size estimates
obtained in the re-analysis of long-term abstinence,
although statistically nonsignificant, are in general
slightly larger in magnitude than those obtained for
short-term abstinence.
The epidemiological study (Murphy, Horton,
Monson, Laird, Sobol, & Leighton 2003) that Dr.
Covey cites as contradicting Hitsman et al (2003) is
irrelevant because the current debate focuses on
smoking cessation treatment outcome. Murphy
et al.’s (2003) data do not permit causal inferences
to be drawn regarding the influence of depression
history on smoking cessation, since they do not
establish the temporality of depression onset vis-a`-vis
cessation. As Murphy and colleagues rightly noted, ‘‘it
was possible that some of the subjects who became
depressed had already quit smoking before the onset
of depression’’ (p. 1666).
In sum, this re-analysis of short- and long-term
abstinence involving only placebo or alternative least
intensive treatment condition yields effect size estimates
Table 1. Results of the re-analysis of effect sizes of short-term abstinence for smokers positive vs. negative for history
of depression treated with placebo or alternative least intensive condition.
Sample for analysis No. studies
No. subjects
dz 95% CI p
a Qw p
bN (Hxz/Hx2)
All treatment trials 13 1215 (413/802) 2.08 2.20, .04 .16 11.43 .49
z Smith et al. (2003) 14 1375 (438/937) 2.10 2.22, .02 .07 12.51 .49
Antidepressant trials only 7 521 (147/374) 2.01 2.21, .18 .87 1.66 .95
z Smith et al. (2003) 8 681 (172/509) 2.07 2.25, .11 .37 3.23 .86
dz, aggregated effect size estimates; CI, confidence interval for the aggregated effect size estimate; Qw, within-class homogeneity
statistic.
ap value for significance level of the aggregated effect size.
bp value for test of within-class homogeneity (nonsignificant value reflects a homogeneous estimate, in which the variability around the
aggregated effect size is no greater than that expected from sample error alone).
Table 2. Results of the re-analysis of effect sizes of long-term abstinence for smokers positive vs. negative for history of
depression treated with placebo or alternative least intensive condition.
Sample for analysis No. studies
No. subjects
dz 95% CI p
a Qw p
bN (Hxz/Hx2)
All treatment trials 10 774 (254/520) 2.10 2.26, .06 .16 2.54 .98
z Smith et al. (2003) 11 934 (279/655) 2.12 2.26, .03 .07 2.94 .98
Antidepressant trials only 7 521 (147/374) 2.14 2.34, .06 .12 0.52 .99
z Smith et al. (2003) 8 681 (172/509) 2.16 2.34, .02 .07 0.74 .99
dz, aggregated effect size estimates; CI, confidence interval for the aggregated effect size estimate; Qw, within-class homogeneity
statistic.
ap value for significance level of the aggregated effect size.
bp value for test of within-class homogeneity (nonsignificant value reflects a homogeneous estimate, in which the variability around the
aggregated effect size is no greater than that expected from sample error alone).
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that are entirely consistent with those reported in
Hitsman et al. (2003), which collapsed across least and
most intensive intervention conditions. Again, the
effect sizes are statistically nonsignificant and below
Cohen’s (1987) minimum standard for a small effect
size (dz~.20). It is important to point out that, even
if statistical significance had been reached, it is
unlikely that effect sizes of the magnitude observed
(dzƒ2.16) would be meaningful clinically. Thus,
although we agree with Dr. Covey that restricting the
meta-analysis to participants randomized to the least
intensive treatment conditions provides a more valid
estimate of depression history’s association with
treatment outcome, doing so does not change our
findings. The evidence again suggests that ‘‘lifetime
history of major depression does not appear to be an
independent risk factor for cessation failure in
smoking cessation treatment’’ (from abstract).
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